Correspondence 0001104659-23-116981 from BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893) (BTAI)
BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893)
Date: Nov. 13, 2023 · CIK: 0001720893 · Accession: 0001104659-23-116981
AI Filing Summary & Sentiment
File numbers found in text: 333-275261
Letter
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
November 13, 2023
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Joshua Gorsky
Re: BioXcel Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-275261
To the addressee set forth above:
BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests the withdrawal of its acceleration request letter filed as correspondence via EDGAR transmission on November 9, 2023, which requested that the Registration Statement on Form S-3 (File No. 333-275261) filed on November 2, 2023 become effective on Tuesday, November 14, 2023, at 9:00 a.m., Washington D.C. time, or as soon as reasonably practicable thereafter. The Company is no longer requesting that such Registration Statement be declared effective at this specific date and time and the Company hereby formally withdraws its request for acceleration of the effective date as stated above.
Furthermore, in accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the Company hereby requests the acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-275261) filed on November 2, 2023, so that it will become effective on November 13, 2023, at 4:30 p.m., Washington D.C. time, or as soon thereafter as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff.
The Company requests that we be notified of such effectiveness by a telephone call to Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 or N. Danny Shulman at (212) 906-4510 and that such effectiveness also be confirmed in writing.
Very truly yours,
BioXcel Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
November 13, 2023
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Joshua Gorsky
Re: BioXcel Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-275261
To the addressee set forth above:
BioXcel Therapeutics, Inc.
(the “Company”) hereby respectfully requests the withdrawal of its acceleration request letter filed as correspondence via
EDGAR transmission on November 9, 2023, which requested that the Registration Statement on Form S-3 (File No. 333-275261)
filed on November 2, 2023 become effective on Tuesday, November 14, 2023, at 9:00 a.m., Washington D.C. time, or as soon as
reasonably practicable thereafter. The Company is no longer requesting that such Registration Statement be declared effective at this
specific date and time and the Company hereby formally withdraws its request for acceleration of the effective date as stated above.
Furthermore, in accordance
with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the Company
hereby requests the acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-275261) filed
on November 2, 2023, so that it will become effective on November 13, 2023, at 4:30 p.m., Washington D.C. time, or as soon thereafter
as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff.
The Company requests that
we be notified of such effectiveness by a telephone call to Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 or
N. Danny Shulman at (212) 906-4510 and that such effectiveness also be confirmed in writing.
Very truly yours,
BioXcel Therapeutics, Inc.
By:
/s/ Richard Steinhart
Richard Steinhart
Chief Financial Officer
cc: Keith L. Halverstam, Latham & Watkins LLP
N. Danny Shulman, Latham & Watkins LLP